癌症恶病质市场规模、份额和成长分析（按产品类型、作用机制、分销管道和地区）- 2025-2032 年产业预测

2023 年全球癌症恶病质市场规模价值 28.3 亿美元，预计将从 2024 年的 29.6 亿美元增长到 2032 年的 42.1 亿美元，预测期内（2025-2032 年）的复合年增长率为 4.5%。

根据美国国家生物技术资讯中心的最新资料，恶病质影响约 80% 的晚期癌症患者，并导致全球 20% 的癌症相关死亡。这种消耗症候群的特征是体重明显下降、厌食、骨质疏鬆和贫血，在癌症、慢性阻塞性肺病和爱滋病毒等慢性疾病中普遍存在，每年在美国影响约 130 万名癌症患者。由于高龄化社会特别容易受到癌症的侵害，开发针对癌症恶病质的治疗方法具有巨大的市场机会。患者数量的增加凸显了创新干预措施的必要性，进一步推动市场扩张并解决肿瘤学领域的关键患者照护挑战。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 监管格局
• 专利分析

癌症恶病质市场规模（按产品类型和复合年增长率） (2025-2032)

• 市场概况
• 黄体素
• 皮质类固醇
• 联合治疗
• 其他的

癌症恶病质市场规模（按作用机制和复合年增长率） (2025-2032)

• 市场概况
• 促进食慾
• 减重稳定剂

癌症恶病质市场规模（按分销管道和复合年增长率） (2025-2032)

• 市场概况
• 医院药房
• 零售药局
• 网路药局

癌症恶病质市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Merck & Co., Inc.（USA）
• Aphios Corporation（USA）
• Helsinn Group（Switzerland）
• Bristol-Myers Squibb Company（USA）
• Pfizer Inc.（USA）
• Eli Lilly and Company（USA）
• Novartis AG（Switzerland）
• Veru Inc.（USA）
• Mylan NV（USA）
• Hikma Pharmaceuticals PLC（UK）
• AbbVie Inc.（USA）
• Amgen Inc.（USA）
• AstraZeneca PLC（UK）
• Johnson & Johnson（USA）
• GlaxoSmithKline PLC（UK）
• F. Hoffmann-La Roche AG（Switzerland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Takeda Pharmaceutical Company Limited（Japan）

结论和建议

Global Cancer Cachexia Market size was valued at USD 2.83 billion in 2023 and is poised to grow from USD 2.96 billion in 2024 to USD 4.21 billion by 2032, growing at a CAGR of 4.5% during the forecast period (2025-2032).

Recent data from the National Center for Biotechnology Information indicates that cachexia affects around 80% of advanced cancer patients, contributing to 20% of cancer-related deaths worldwide. This wasting syndrome, characterized by significant weight loss, anorexia, osteoporosis, and anemia, is prevalent in chronic diseases like cancer, COPD, and HIV, impacting approximately 1.3 million cancer patients annually in the U.S. As the global cancer incidence continues to rise, so does the potential market for cachexia treatments. With the aging population particularly vulnerable to cancer, there is substantial market opportunity for developing therapies targeting cancer cachexia. The growing patient population emphasizes the need for innovative interventions, further propelling market expansion and addressing critical patient care challenges in the oncology space.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Cachexia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Cachexia Market Segments Analysis

Global Cancer Cachexia Market is segmented by Product Type, Mechanism of Action, Distribution Channel and Region. Based on Product Type, the market is segmented into Progestogens, Corticosteroids, Combination Therapies and Others. Based on Mechanism of Action, the market is segmented into Appetite Stimulators and Weight Loss Stabilizers. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Cachexia Market

The global Cancer Cachexia market is primarily driven by the limited treatment options currently available for managing cachexia in cancer patients, which predominantly include progestogens and corticosteroids. While these medications have demonstrated some effectiveness, the variability in clinical outcomes highlights a significant unmet need, as there are no specific drug approvals tailored for this condition. This gap in therapeutic solutions presents an opportunity for market participants to engage in research and development efforts aimed at creating innovative treatments. As companies strive to address this deficiency, the global market is poised for growth through the introduction of novel drug candidates.

Restraints in the Global Cancer Cachexia Market

Although the global cancer cachexia market is witnessing a rise in prevalence, several challenges are hindering its expansion. These include the exorbitant costs linked to cancer and its adjunct treatments, along with inadequate drug reimbursement in developing nations. Treatment expenses for cancer patients suffering from cachexia are generally higher than those for non-cachexia patients, resulting in significant out-of-pocket expenses. Additionally, the scarcity of approved therapeutic options for this condition further hampers market growth. Consequently, these factors are likely to lead to a gradual increase in the market throughout the projected timeframe.

Market Trends of the Global Cancer Cachexia Market

The global cancer cachexia market is witnessing a notable trend towards the adoption of combination therapies, driven by the limitations of traditional single-drug approaches, which often yield insufficient therapeutic benefits. With a scarcity of approved drugs specifically for cancer cachexia, healthcare providers are increasingly embracing multicomponent strategies that integrate both pharmacological and non-pharmacological interventions. Clinical trials have demonstrated significant improvements in lean body mass (LBM) among patients receiving these combination therapies. As healthcare professionals advocate for these multifaceted treatment regimens, patient acceptance is rising, thereby fueling demand and expanding opportunities in the global cancer cachexia market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Cancer Cachexia Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Progestogens
• Corticosteroids
• Combination Therapies
• Others

Global Cancer Cachexia Market Size by Mechanism of Action & CAGR (2025-2032)

• Market Overview
• Appetite Stimulators
• Weight Loss Stabilizers

Global Cancer Cachexia Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Cancer Cachexia Market Size & CAGR (2025-2032)

• North America (Product Type, Mechanism of Action, Distribution Channel)
  • US
  • Canada
• Europe (Product Type, Mechanism of Action, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Mechanism of Action, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Mechanism of Action, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Mechanism of Action, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aphios Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Helsinn Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veru Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations